e-learning
resources
London 2016
Tuesday, 06.09.2016
Non-inflammatory COPD monitoring
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD
Francesca Simioli (Naples, Italy), Francesca Simioli, Maria Martino, Giacomo Spurio Vennarucci, Lucia Morrone, Antonio Molino, Mauro Mormile, Anna Agnese Stanziola, Maria D’Amato
Source:
International Congress 2016 – Non-inflammatory COPD monitoring
Session:
Non-inflammatory COPD monitoring
Session type:
Oral Presentation
Number:
3523
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Francesca Simioli (Naples, Italy), Francesca Simioli, Maria Martino, Giacomo Spurio Vennarucci, Lucia Morrone, Antonio Molino, Mauro Mormile, Anna Agnese Stanziola, Maria D’Amato. Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD. Eur Respir J 2016; 48: Suppl. 60, 3523
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Bronchodilator response of advanced lung function parameters depending on COPD severity
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016
The effects of bronchodilators on regional lung sound distribution in patients with COPD
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Effects of inhaled furosemide on exercise capacity and on dyspnea in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Prevalence of small airway dysfunction among GOLD stages in COPD patients
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016
First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Effects of ciclesonide on the management of stable COPD with airway eosinophilia
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Body-plethysmographic measurements of bronchodilator response in stable COPD
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Lung function change and exacerbations in patients with COPD in the WISDOM study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
QVA149 provides superior peak lung function in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Additive effect of targeted lung denervation plus drug in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Effects of tiotropium on lung function in current smokers and never smokers with asthma
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept